Modulation of microglial phenotypes improves sepsis-induced hippocampus-dependent cognitive impairments and decreases brain inflammation in an animal model of sepsis

Clin Sci (Lond). 2020 Apr 17;134(7):765-776. doi: 10.1042/CS20191322.

Abstract

Background: In order to modulate microglial phenotypes in vivo, M1 microglia were depleted by administration of gadolinium chloride and the expression of M2 microglia was induced by IL-4 administration in an animal model of sepsis to better characterize the role of microglial phenotypes in sepsis-induced brain dysfunction.

Methods: Wistar rats were submitted to sham or cecal ligation and perforation (CLP) and treated with IL-4 or GdCl3. Animals were submitted to behavioral tests 10 days after surgery. In a separated cohort of animals at 24 h, 3 and 10 days after surgery, hippocampus was removed and cytokine levels, M1/M2 markers and CKIP-1 levels were determined.

Results: Modulation of microglia by IL-4 and GdCl3 was associated with an improvement in long-term cognitive impairment. When treated with IL-4 and GdCl3, the reduction of pro-inflammatory cytokines was apparent in almost all analyzed time points. Additionally, CD11b and iNOS were increased after CLP at all time points, and both IL-4 and GdCl3 treatments were able to reverse this. There was a significant decrease in CD11b gene expression in the CLP+GdCl3 group. IL-4 treatment was able to decrease iNOS expression after sepsis. Furthermore, there was an increase of CKIP-1 in the hippocampus of GdCl3 and IL-4 treated animals 10 days after CLP induction.

Conclusions: GdCl3 and IL-4 are able to manipulate microglial phenotype in an animal models of sepsis, by increasing the polarization toward an M2 phenotype IL-4 and GdCl3 treatment was associated with decreased brain inflammation and functional recovery.

Keywords: M1/M2; microglia; neuroinflammation; sepsis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Inflammatory Agents / pharmacology*
  • Behavior, Animal / drug effects*
  • CD11b Antigen / metabolism
  • Carrier Proteins / metabolism
  • Cognition / drug effects*
  • Cognitive Dysfunction / metabolism
  • Cognitive Dysfunction / pathology
  • Cognitive Dysfunction / prevention & control*
  • Cognitive Dysfunction / psychology
  • Cytokines / metabolism
  • Disease Models, Animal
  • Encephalitis / metabolism
  • Encephalitis / pathology
  • Encephalitis / physiopathology
  • Encephalitis / prevention & control*
  • Gadolinium / pharmacology*
  • Hippocampus / drug effects*
  • Hippocampus / metabolism
  • Hippocampus / pathology
  • Hippocampus / physiopathology
  • Inflammation Mediators / metabolism
  • Interleukin-4 / pharmacology*
  • Microglia / drug effects*
  • Microglia / metabolism
  • Microglia / pathology
  • Nitric Oxide Synthase Type II / metabolism
  • Phenotype
  • Rats, Wistar
  • Sepsis / drug therapy*
  • Sepsis / metabolism
  • Sepsis / pathology
  • Sepsis / physiopathology
  • Time Factors

Substances

  • Anti-Inflammatory Agents
  • CD11b Antigen
  • CKIP-1 protein, rat
  • Carrier Proteins
  • Cytokines
  • Inflammation Mediators
  • Interleukin-4
  • Gadolinium
  • Nitric Oxide Synthase Type II
  • Nos2 protein, rat
  • gadolinium chloride